BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pratama MY, Visintin A, Crocè LS, Tiribelli C, Pascut D. Circulatory miRNA as a Biomarker for Therapy Response and Disease-Free Survival in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2810. [PMID: 33003646 DOI: 10.3390/cancers12102810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Fondevila F, Fernández-Palanca P, Méndez-Blanco C, Payo-Serafín T, Lozano E, Marin JJG, González-Gallego J, Mauriz JL. Association of FOXO3 Expression with Tumor Pathogenesis, Prognosis and Clinicopathological Features in Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis. Cancers (Basel) 2021;13:5349. [PMID: 34771514 DOI: 10.3390/cancers13215349] [Reference Citation Analysis]
2 Guan MC, Ouyang W, Wang MD, Liang L, Li N, Fu TT, Shen F, Lau WY, Xu QR, Huang DS, Zhu H, Yang T. Biomarkers for hepatocellular carcinoma based on body fluids and feces. World J Gastrointest Oncol 2021; 13(5): 351-365 [PMID: 34040698 DOI: 10.4251/wjgo.v13.i5.351] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Zelli V, Compagnoni C, Capelli R, Corrente A, Di Vito Nolfi M, Zazzeroni F, Alesse E, Tessitore A. Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma. Front Oncol 2022;12:940056. [DOI: 10.3389/fonc.2022.940056] [Reference Citation Analysis]
4 Chen S, Fu Z, Wen S, Yang X, Yu C, Zhou W, Lin Y, Lv Y. Expression and Diagnostic Value of miR-497 and miR-1246 in Hepatocellular Carcinoma. Front Genet 2021;12:666306. [PMID: 34163524 DOI: 10.3389/fgene.2021.666306] [Reference Citation Analysis]